Company News

Two doctors sitting and looking at an iPad screen together

Press Release

ION Solutions Collaborates with Grifols to Expand Suite of Pharmacy Offerings for Specialty Physician Practices

March 2021

Press Release

ION & IPN Solutions Collaborate with Annexus Health to Offer AssistPoint to Specialty Physician Practices

October 2020

Industry Spotlights

Find important details about clinical study results for first-line CLL treatment.

June 2021

NOW APPROVED for relapsed / refractory RCC

June 2021

Your patients have access to strong coverage

June 2021

What is your treatment approach in advanced ovarian cancer?

June 2021

KRAS G12C is now an actionable mutation

May 2021

Explore a new treatment option for patients with advanced NSCLC

May 2021

TAGRISSO® (osimertinib): The new indication

May 2021

Now approved as a first-line treatment option in advanced NSCLC

May 2021

Help patients with R/R MZL/FL get access to a new treatment

May 2021

Preparing to initiate patients on CLL treatment?

April 2021

CLL patients may benefit from Tx that has a fixed duration

April 2021

Support to Help Your Patients Access UKONIQ™ (umbralisib)

April 2021

LIBTAYO® (cemiplimab-rwlc) now approved in a new indication

April 2021

UDENYCA® (pegfilgrastim-cbqv) *Aetna* 2021 Payer Coverage Update

April 2021

MONJUVI® (tafasitamab-cxix) J-code J9349 available

April 2021

UDENYCA® (pegfilgrastim-cbqv) Anthem 2021 Payer Coverage Update

March 2021

Ordering ORGOVYX™ (relugolix)

March 2021

Introducing PEPAXTO® (melphalan flufenamide)

March 2021

XTANDI (enzalutamide) Tablet Formulation Is Available

March 2021

AVASTIN®, HERCEPTIN®, and RITUXAN®: It's likely your patients are covered

March 2021

Introducing COSELA™ (trilaciclib): Now available

March 2021

TAGRISSO® (osimertinib): The new indication

March 2021

Why is HRD status critical in newly diagnosed advanced ovarian cancer?

February 2021

Help patients with R/R MZL/FL get access to a new treatment

February 2021

New NCCN Category 1 recommendation for CLL

February 2021

Now approved: CABOMETYX® (cabozantinib) + OPDIVO® (nivolumab)

February 2021

New indication, now approved: ENHERTU® (fam-trastuzumab deruxtecan-nxki)

February 2021

Did you know this immunotherapy has 5 lung approvals?

February 2021

Permanent J-Code for fixed-dose HER2+ breast cancer product

February 2021

A new treatment option for resectable NSCLC

February 2021

See a new dosing option for unresectable Stage III NSCLC

January 2021

Stay Up-to-Date With the Latest NCCN Guidelines for AML

January 2021

XPOVIO® (selinexor): New Indication Now Approved

January 2021